afami-cel,nivolumab,adp-a2m4cd8
adaptimmune therapeutics,bms
['a2m4cd8', 'adp-a2m4', 'surpass', '$adap']
on september 9, $adap held their #esmo22 investor event (press release: / presentation: highlighting the clinical results from adp-a2m4cd8 s ph1 #surpasstrial ( presented at #esmo22: 
Contextualized #cell #therapy #market #insights. Syndicated services and customized consulting solutions for #lifesciences and #biotwitter.